%PDF-1.4
%
42 0 obj
<>
endobj
39 0 obj
<>
endobj
102 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-10T12:13:27Z
2024-03-28T03:55:19-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T03:55:19-07:00
application/pdf
Heather
2004-47.feb
uuid:e97f6ca4-1dd1-11b2-0a00-0209275d6100
uuid:e97f6ca6-1dd1-11b2-0a00-aa0000000000
endstream
endobj
28 0 obj
<>
endobj
29 0 obj
<>
endobj
43 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 18 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 20 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
112 0 obj
[117 0 R]
endobj
113 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
/GS0 gs
104.631 82.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 82.25 407.5 -10.833 re
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.0914 Tw 10 0 0 10 53.468 735.6616 Tm
(patient had a history of symmetrical muscle weakness and)Tj
0.11571 Tw 0 -1.2 TD
(rash, as well as muscle biopsy and electromyography evi-)Tj
0.2549 Tw T*
(dence of myositis, establishing the diagnosis of definite)Tj
-0.0002 Tc 0 Tw T*
(DM)Tj
0 Tc 7.5 0 0 7.5 69.5764 702.9616 Tm
(1,2)Tj
10 0 0 10 78.9514 699.6616 Tm
(.)Tj
-0.00011 Tc 0.1907 Tw -1.3483 -1.2 Td
[(W)80 (e describe the presence of bilateral orbital myositis,)]TJ
0.1955 Tw -1.2 -1.2 Td
(occurring in the course of a previously undiagnosed and)Tj
0.1907 Tw T*
[(untreated dermatomyositis. )55 (Although ocular myositis is a)]TJ
0.00169 Tw T*
(very rare manifestation of DM)Tj
0 Tc 0 Tw 7.5 0 0 7.5 175.6946 654.9615 Tm
(4,5)Tj
-0.00011 Tc 0.00169 Tw 10 0 0 10 185.0696 651.6616 Tm
(, it might be overlooked by)Tj
0.02499 Tw -13.1602 -1.2 Td
(clinicians who are not aware of this complication.)Tj
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES )Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 60.468 605.6616 Tm
[(1.)-875 (Olsen JN, )18 (W)80 (ortmann LR. Inflammatory and metabolic disease of)]TJ
1.675 -1.25 Td
[(muscle. In: Klippel HJ, editor)55 (. Primer on the rheumatic diseases.)]TJ
0 -1.25 TD
[(Atlanta: )18 (The )55 (Arthritis Foundation; 1998:276-82.)]TJ
-1.675 -1.25 Td
[(2.)-875 (Medsger )18 (T)80 (A, Oddis )18 (VC. Inflammatory muscle disease: clinical )]TJ
1.675 -1.25 Td
[(features. In: Klippel HJ, Dieppe )55 (AP)111 (, editors. Rheumatology)65 (. New)]TJ
0 Tc T*
[(Y)100 (ork: Mosby; 1998:345-57.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875 (Adams RD. Polymyositis and other acute and subacute myopathic)]TJ
1.675 -1.25 Td
[(paralyses. In: )55 (Adams RD, )18 (V)60 (ictor M, editors. Principles of )]TJ
T*
[(neurology)65 (. New )37 (Y)100 (ork: McGraw-Hill Health Professions Division;)]TJ
0 Tc 0 Tw T*
[(1989:1)37 (104-15.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875 (Berkhof)18 (f M, Sturzenegger M, Schroth G, Hess CW)92 (. Ocular )]TJ
1.675 -1.25 Td
(myositis [German]. Nervenartz 1997;68:792-800.)Tj
-1.675 -1.25 Td
[(5.)-875 (Lacey B, Chang )18 (W)92 (, Rootman J. Nonthyroid causes of extraocular)]TJ
1.675 -1.25 Td
(muscle disease. Surv Ophthalmol 1999;44:187-213.)Tj
31.325 32.671 Td
[(6.)-875 (Rosenfalck Poul. Electromyography in normal subjects of dif)18 (ferent)]TJ
1.675 -1.25 Td
[(age. In: Fuglsang-Frederiksen )55 (A, editor)55 (. Methods in clinical)]TJ
0 Tc T*
[(Neurophysiology)65 (. Copenhagen;1991:47-52.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875 (Cherin P)111 (, Herson S, )18 (W)80 (echsler B, et al. Ef)18 (ficacy of intravenous )]TJ
1.675 -1.25 Td
(gammaglobulin therapy in chronic refractory polymyositis and )Tj
T*
[(dermatomyositis: an open study with 20 adult patients. )55 (Am J Med)]TJ
0 Tc 0 Tw T*
(1991;91:162-8.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875 (Cherin P)111 (, Pelletier S, )18 (T)70 (eixeira )55 (A, et al. Results and long-term )]TJ
1.675 -1.25 Td
(followup of intravenous immunoglobulin infusions in chronic)Tj
T*
(refractory polymyositis: an open study with 35 adult patients.)Tj
T*
(Arthritis Rheum 2002;46:467-74.)Tj
-1.675 -1.25 Td
[(9.)-875 (Dalacas MC, Illa I, Dambrosia JM, et al. )55 (A)-220 (controlled trial of )]TJ
1.675 -1.25 Td
(high-dose intravenous immune globulin infusions as treatment for)Tj
T*
(dermatomyositis. N Engl J Med 1993;329:1993-2000.)Tj
-2.175 -1.25 Td
[(10.)-875 (Nakatani-Enomoto S, )55 (Aizawa H, Koyama S, Haga )18 (T)74 (, )18 (T)70 (akahashi )]TJ
2.175 -1.25 Td
[(J, Kikuchi K. )55 (A)-220 (patient of recurrent orbital myositis with good)]TJ
T*
[(response to high-dose intravenous immunoglobulin therapy)65 (. Rinsho)]TJ
T*
(Shinkeigaku 2002;42:154-7.)Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Siatkowski RM, Capo H, Byrne SF)80 (, et al. Clinical and echographic)]TJ
2.1381 -1.25 Td
[(findings in idiopathic orbital myositis. )55 (Am J Ophthalmol)]TJ
0 Tc 0 Tw T*
[(1994;1)37 (18:343-50.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875 (Garcia J. MRI in inflammatory myopathies. Skel Radiol)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(2000;29:425-38.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875 (Smith )55 (AG, Urbanits S, Blaivas M, Grisold )18 (W)92 (, Russell )18 (WJ. Clinical)]TJ
2.175 -1.25 Td
(and pathologic features of focal myositis. Muscle Nerve)Tj
0 Tc 0 Tw T*
(2000;23:1569-75.)Tj
ET
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
8 0 0 8 545.468 56.4344 Tm
(381)Tj
-0.00011 Tc 0.02499 Tw -61.367 0.01295 Td
(Kokotis, et al: Bilateral ocular myositis)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_3 8 Tf
106.328 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
22 0 obj
<>stream
8;Z\5>7Q9>%*ST&kj(p;9q8MrP_/ZInYAb'OG@2b!d")=0U,jH"4^gphKLM[`GeBjt:+jQ2BNr
FY4D@+j!],S@Wdf%`GJXg_V/_8_r&1rNe&3)[@IbH>
@$3G5+cKWhSnhSpWUKJm`u0Cm-*UR?IM/n8F;m1d3lVNh0TEQ84QKM@
endstream
endobj
26 0 obj
[/Indexed/DeviceRGB 255 25 0 R]
endobj
25 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
55 0 obj
<>
endobj
66 0 obj
<>
endobj
49 0 obj
<>
endobj
84 0 obj
<>
endobj
107 0 obj
<>
endobj
48 0 obj
<>
endobj
76 0 obj
<>stream
HU{PSg7A;*R@""J$BH#@Đy b!JUŷZunl;hsӏݨv93g9;9|8p%x|FEBxϻ8=AT<qB8^hE,+9,81n7zOHgWXVS¹{$\O"aRI{,A!J
W ʅ2\$vFw,˅ B,!I$IJ
CR2C$\AP*uD8I ?cӰI̝x.̉?-qְЉX9G°T>iF'F]&ȓ̕^6r\OHpkb#?1/'5rp'{Lqst <<^{x0E<8Ubj!^:4%yKFԉ[/40HU|Ph;0s$|U]RWY\9D}C(2\a`xpڲm,T%xC>{TLZ
S䕉f5>|,=J#] 4{Fg]9կV]
LF{f̾,6*K|^[qy kdsˬAOw,h,`UXUa.mH_(@q- @_ VVb\YPY-{D~O/|sLR$Yq
kvognȋhs%Yw#fݾu6yDٙt!X]